- Home
- JBGS vs ERAS Comparison
JBGS vs ERAS Comparison
Compare JBGS & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JBGS | ERAS |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | JBGS | ERAS |
|---|---|---|
| Price | $17.05 | $3.42 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $18.00 | $3.71 |
| AVG Volume (30 Days) | 650.5K | ★ 2.6M |
| Earning Date | 02-17-2026 | 11-12-2025 |
| Dividend Yield | ★ 4.11% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $501,226,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.79 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.28 | $1.01 |
| 52 Week High | $24.30 | $3.80 |
Technical Indicators
Market Signals| Indicator | JBGS | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 36.78 | 55.97 |
| Support Level | $16.77 | $3.36 |
| Resistance Level | $17.51 | $3.77 |
| Average True Range (ATR) | 0.43 | 0.24 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 20.72 | 40.77 |
Price Performance
Historical ComparisonAbout JBGS JBG SMITH Properties
JBG SMITH Properties is a real estate investment trust based in the United States. It owns, operates, invests in, and develops real estate assets concentrated in amenity-rich, metro-served submarkets in and around Washington, DC. In addition, the company also provides fee-based real estate services to legacy funds through its third-party real estate services business. The operating segments of the company are commercial, multifamily, and third-party asset management and real estate services. It generates maximum revenue from the commercial segment.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.